Get our Free Patent Expiration, Litigation, and Drug Price Updates

Serving hundreds of leading biopharmaceutical companies globally:

Chubb
QuintilesIMS
Cantor Fitzgerald
Queensland Health
Citi
McKesson

Generated: May 26, 2019

DrugPatentWatch Database Preview

Details for Patent: 7,112,592

« Back to Dashboard

Which drugs does patent 7,112,592 protect, and when does it expire?

Patent 7,112,592 protects AVYCAZ and is included in one NDA.

This patent has fifty-seven patent family members in forty-two countries.

Summary for Patent: 7,112,592
Title:Azabicyclic compounds, preparation thereof and use as medicines, in particular as antibacterial agents
Abstract: The invention relates to new heterocyclic compounds of general formula (I), and their salts with a base or an acid: ##STR00001## The invention also relates to a process for the preparation of these compounds as well as their use as medicaments, in particular as anti-bacterial agents.
Inventor(s): Lampilas; Maxime (Romainville, FR), Aszodi; Jozsef (Tucson, AZ), Rowlands; David Alan (Poissy, FR), Fromentin; Claude (Paris, FR)
Assignee: Aventis Pharma S.A. (FR)
Application Number:10/343,315
Prior Art and Litigation SupportOrder Prior Art and Litigation support for Patent 7,112,592
Patent Claim Types:
see list of patent claims
Composition; Compound; Use;

Drugs Protected by US Patent 7,112,592

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Allergan Sales Llc AVYCAZ avibactam sodium; ceftazidime POWDER;IV (INFUSION) 206494-001 Feb 25, 2015 RX Yes Yes ➤ Sign Up ➤ Sign Up Y Y A METHOD OF TREATING BACTERIAL INFECTIONS IN HOSPITAL-ACQUIRED BACTERIAL PNEUMONIA AND VENTILATOR-ASSOCIATED BACTERIAL PNENUMONIA (HABP/VABP) PATIENTS COMPRISING ADMINISTERING A BACTERICIDALLY EFFECTIVE AMOUNT OF AVIBACTAM SODIUM ➤ Sign Up
Allergan Sales Llc AVYCAZ avibactam sodium; ceftazidime POWDER;IV (INFUSION) 206494-001 Feb 25, 2015 RX Yes Yes ➤ Sign Up ➤ Sign Up Y Y METHOD OF TREATING BACTERIAL INFECTIONS ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate

Subscribe to access the full database, or try a Free Trial

Foreign Priority and PCT Information for Patent: 7,112,592

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
France00 10121Aug 1, 2000
PCT Information
PCT FiledJuly 24, 2001PCT Application Number:PCT/FR01/02418
PCT Publication Date:February 07, 2002PCT Publication Number: WO02/10172

International Family Members for US Patent 7,112,592

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
African Regional IP Organization (ARIPO) 1614 ➤ Sign Up
Argentina 031716 ➤ Sign Up
Austria 263768 ➤ Sign Up
Australia 2001279905 ➤ Sign Up
Australia 7990501 ➤ Sign Up
Bulgaria 107497 ➤ Sign Up
Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

Subscribe to access the full database, or try a Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Fish and Richardson
UBS
QuintilesIMS
Citi
Julphar
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.